NCT06720909 Mindfulness And Placebo for Pain (MAPP) Study
| NCT ID | NCT06720909 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Arizona State University |
| Condition | Chronic Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 45 participants |
| Start Date | 2025-01-27 |
| Primary Completion | 2027-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 45 participants in total. It began in 2025-01-27 with a primary completion date of 2027-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study proposes a three-arm randomized-controlled trial (RCT) that evaluates the feasibility and acceptability of combining a mindfulness-based therapy (MBT) and open-label placebo (OLP) treatment for individuals with chronic pain. Individuals with chronic pain will be recruited to participate in an 8-week trial, with a subsequent 3-month post-treatment follow-up. Participants will be randomly assigned to one of the following three conditions: 1. Mindfulness-Based Stress Reduction (MBSR) 2. OLP treatment 3. combination of MBSR and OLP treatment
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years old; 2. ability to speak, write, and read in English; 3. physical pain present on at least half the days in the past 3 months; and 4. average past week pain severity rating ≥3 on a 0-10 Numerical Rating Scale. Exclusion Criteria: 1. acute pain due to recent injury or surgery; 2. self-reporting of chronic malignant pain (e.g., cancer, HIV); 3. self-reporting of Raynaud's disease (those who can be contraindicated for cold pressor testing); 4. severe psychopathology (e.g., a psychotic disorder) or significant cognitive deficits judged to interfere with study procedures; 5. currently pregnant or breastfeeding; 6. inability to discontinue use of vitamin B2 supplements or a multivitamin containing vitamin B2 throughout the study period (these interfere with riboflavin tracer-OLP treatment adherence-monitoring); 7. inability to commit to study period.
Contact & Investigator
Chung Jung Mun, PhD
PRINCIPAL INVESTIGATOR
Arizona State University
Frequently Asked Questions
Who can join the NCT06720909 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06720909 currently recruiting?
Yes, NCT06720909 is actively recruiting participants. Contact the research team at chungjung.mun@asu.edu for enrollment information.
Where is the NCT06720909 trial being conducted?
This trial is being conducted at Phoenix, United States, Phoenix, United States.
Who is sponsoring the NCT06720909 clinical trial?
NCT06720909 is sponsored by Arizona State University. The principal investigator is Chung Jung Mun, PhD at Arizona State University. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.